(Q24185977)

14

0 references

Goran Bjelakovic

11

0 references

Jian Ping Liu

13

object named as

Jian Ping Liu

0 references

Ronald L Koretz

15

object named as

Ronald L Koretz

0 references

author name string

Janus C Jakobsen

1

0 references

Emil Eik Nielsen

2

0 references

Joshua Feinberg

3

0 references

Kristina Fobian

4

0 references

Kiran Kumar Katakam

5

0 references

Goran Hauser

6

0 references

Goran Poropat

7

0 references

Snezana Djurisic

8

0 references

Karl Heinz Weiss

9

0 references

Milica Bjelakovic

10

0 references

Sarah Louise Klingenberg

Cochrane Database of Systematic Reviews

12

0 references

publication date

5 April 2016

0 references

published in

0 references

cites work

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Ribavirin monotherapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Ribavirin plus interferon versus interferon for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Virology and cell biology of the hepatitis C virus life cycle: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

New treatment strategies for hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Global epidemiology and genotype distribution of the hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

GRADE guidelines: 2. Framing the question and deciding on important outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

GRADE guidelines: 5. Rating the quality of evidence--publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

GRADE guidelines: 7. Rating the quality of evidence--inconsistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

GRADE guidelines: 8. Rating the quality of evidence--indirectness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

GRADE guidelines: 9. Rating up the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Industry sponsorship and research outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Treating viral hepatitis C: efficacy, side effects, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Global distribution and prevalence of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

When does mother to child transmission of hepatitis C virus occur?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Impact of new treatment options for hepatitis C virus infection in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Estimating required information size by quantifying diversity in random-effects model meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

GRADE guidelines 6. Rating the quality of evidence—imprecision

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143

EASL Recommendations on Treatment of Hepatitis C 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD012143